Drug Trial Radar · NCT03260023
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
143
Actual
Start
Sep 1, 2017
Primary completion
Sep 18, 2024
Study completion Dec 2026
Sponsor
- Lead sponsor
- TransgeneIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany; EMD Serono Research & Development Institute, Inc.; Pfizer
- First posted
- Aug 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation. In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies. In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in participants with HPV-16 positive advanced malignancies. In both phases, evaluation of tumor response will be done locally according to RECIST 1.1. All participants will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.
Conditions
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
Interventions
TG4001Biological
PhIb: Dose escalation PhII: Established RP2D for TG4001
AvelumabDrug
Anti PD-L1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced MalignanciesTime frame: From Day 1 to Day 28
- Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1Time frame: From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
- Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
- Progression Free Survival (PFS) Phase II Part 2 Cohort A by StratificationTime frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic
Jacksonville, Florida
Mayo Clinic
Rochester, Minnesota
I.C.O. Paul Papin
Angers, France
CHU Besançon
Besançon, France
Hôpital Saint André - CHU de Bordeaux
Bordeaux, France
Hôpitaux Civils de Colmar - Hôpital Pasteur
Colmar, France
CLCC Georges-François Leclerc
Dijon, France
Centre Léon Bérard
Lyon, France
Hopital de la Timone
Marseille, France
Institut Curie
Paris, France
I.C.O. Gauducheau
Saint-Herblain, France
Centre Paul Strauss - ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
Institut Claudius Regaud - IUCT - Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
ICO Badalona - Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Virgen de las Nieves
Granada, Spain
Fundación de Investigación biomédica H. 12 de Octubre
Madrid, Spain
Fundación de Investigación Biomédica Hospital Clínico San Carlos
Madrid, Spain
Hospital Virgen de La Victoria
Málaga, Spain
Hospital General de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.